Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Blatchford

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Circulation|April 4, 2022
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE TrialMikhail N Kosiborod, Christiane E Angermann, Sean P Collins, et al.
European Journal of Heart Failure|July 9, 2024
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSEJoão Pedro Ferreira, Jonathan P Blatchford, John R Teerlink, et al.
European Journal of Heart Failure|August 4, 2023
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSEJoão Pedro Ferreira, Jonathan P Blatchford, John R Teerlink, et al.
Nature Medicine|March 1, 2022
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A Voors, Christiane E Angermann, John R Teerlink, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Circulation|April 4, 2022
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE TrialMikhail N Kosiborod, Christiane E Angermann, Sean P Collins, et al.
European Journal of Heart Failure|July 9, 2024
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSEJoão Pedro Ferreira, Jonathan P Blatchford, John R Teerlink, et al.
European Journal of Heart Failure|August 4, 2023
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSEJoão Pedro Ferreira, Jonathan P Blatchford, John R Teerlink, et al.
Nature Medicine|March 1, 2022
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A Voors, Christiane E Angermann, John R Teerlink, et al.
Pageof 2